The endocannabinoid system and psychiatric disorders

Experimental Neurology

Volumn 224, Issue 1, 2010, Pages 3-14

  Parolaro, Daniela ^a,b   Realini, Natalia ^a   Vigano, Daniela ^a,b   Guidali, Cinzia ^a   Rubino, Tiziana ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Zardi Gori Foundation   (Italy)

Author keywords

Anxiety; Depression; Endocannabinoid system; Schizophrenia

Indexed keywords

ANANDAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; CLOZAPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; HALOPERIDOL; RIMONABANT;

ABSENCE OF SIDE EFFECTS; ANHEDONIA; ANXIETY DISORDER; ARTICLE; CANNABIS SMOKING; CHRONIC STRESS; CINGULATE GYRUS; COGNITIVE DEFECT; COPING BEHAVIOR; DEPRESSION; DOPAMINE BRAIN LEVEL; DRUG DOSE INCREASE; DRUG TOLERABILITY; HUMAN; LOCOMOTION; MOOD DISORDER; NERVE CELL NETWORK; NEUROTRANSMISSION; NONHUMAN; OBESITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSORY GATING; SEROTONIN BRAIN LEVEL; SOCIAL ISOLATION; STEREOTYPY; VENTRAL TEGMENTUM; WORKING MEMORY;

EID: 77953707182     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.018     Document Type: Review

References (128)

1. Aguiar D.C., Terzian A.L., Guimaraes F.S., Moreira F.A. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl.) 2009, 205:217-225.
2. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
3. Aso E., Ozaita A., Valdizan E.M., Ledent C., Pazos A., Maldonado R., Valverde O. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J. Neurochem. 2008, 105:565-572.
4. Ballmaier M., Bortolato M., Rizzetti C., Zoli M., Gessa G., Heinz A., Spano P. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 2007, 32:2098-2107.
5. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 2007, 27:11700-11711.
6. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
7. Beyer C.E., Piesla M.J., Dwyer J.M., Platt B., Shen R., Rahman Z., Hughes Z.A., Samad T.A., Whiteside G.T. Depression-like phenotype following chronic treatment with rimonabant: A link between CB1 receptors and mood disorders. Program No. 60.7/N21. 2009 Neuroscience Meeting Planner 2009, Society for Neuroscience, Chicago, IL, Online.
8. Bortolato M., Aru G.N., Frau R., Orru M., Luckey G.C., Boi G., Gessa G.L. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl.) 2005, 177:264-271.
9. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 2007, 62:1103-1110.
10. Bubeníková-Valesová V., Horácek J., Vrajová M., Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 2008, 32:1014-1023.
11. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
12. Chavarria-Siles I., Contreras-Rojas J., Hare E., Walss-Bass C., Quezada P., Dassori A., Contreras S., Medina R., Ramirez M., Salazar R., Raventos H., Escamilla M.A. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147:279-284.
13. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003, 2:5.
14. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
15. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., Trzaskos J., Caboche J., Girault J.A. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 2003, 23:2371-2382.
16. Dissanayake D.W., Zachariou M., Marsden C.A., Mason R. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55, 212-2. Neuropharmacology 2008, 55:1397-1404.
17. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., Heindel W., Young R., Morris P., Arolt V., Deckert J., Suslow T., Baune B.T. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur. Neuropsychopharmacol. 2008, 18:751-759.
18. Drew M.R., Hen R. Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol. Disord. Drug Targets 2007, 6:205-218.
19. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:413-431.
20. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
21. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65:772-784.
22. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000, 14:1-21.
23. Ferrer B., Gorriti M.A., Palomino A., Gornemann I., de Diego Y., Bermudez-Silva F.J., Bilbao A., Fernandez-Espejo E., Moratalla R., Navarro M., Rodriguez de Fonseca F. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. Eur. J. Pharmacol. 2007, 559:180-183.
24. Finn D.P. Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance. Immunobiology 2009, (Electronic publication ahead of print).
25. Fraser G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci. Ther. 2009, 15:84-88.
26. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkotter J., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004, 29:2108-2114.
27. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
28. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 2005, 102:18620-18625.
29. Goncalves M.B., Suetterlin P., Yip P., Molina-Holgado F., Walker D.J., Oudin M.J., Zentar M.P., Pollard S., Yáñez-Muñoz R.J., Williams G., Walsh F.S., Pangalos M.N., Doherty P. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol. Cell. Neurosci. 2008, 38:526-536.
30. Gorriti M.A., Rodriguez de Fonseca F., Navarro M., Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur. J. Pharmacol. 1999, 365:133-142.
31. Gorriti M.A., Ferrer B., del Arco I., Bermudez-Silva F.J., de Diego Y., Fernandez-Espejo E., Navarro M., Rodriguez de Fonseca F. Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. Pharmacol. Biochem. Behav. 2005, 81:71-77.
32. Gorzalka B.B., Hill M.N., Hillard C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci. Biobehav. Rev. 2008, 32:1152-1160.
33. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 2005, 57:261-267.
34. Guidali C., Viganò D., Petrosino S., Zamberletti E., Realini N., Binelli G., Rubino T., Di Marzo V., Parolaro D. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int. J. Neuropsychopharmacol. 2010, 3:1-12. (Electronic publication ahead of print, Mar).
35. Hajos N., Katona I., Naiem S.S., Mackie K., Ledent C., Mody I., Freund T.F. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci. 2000, 12:3239-3249.
36. Hajos M., Hoffmann W.E., Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol. Psychiatry 2008, 63:1075-1083.
37. Hall W., Degenhardt L., Teesson M. Cannabis use and psychotic disorders: an update. Drug Alcohol Rev. 2004, 23:433-443.
38. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 2002, 16:1395-1398.
39. Haller J., Varga B., Ledent C., Barna I., Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 2004, 19:1906-1912.
40. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 2004, 15:299-304.
41. Haller J., Szirmai M., Varga B., Ledent C., Freund T.F. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav. Pharmacol. 2005, 16:415-422.
42. Haller J., Barna I., Barsvari B., Gyimesi Pelczer K., Yasar S., Panlilio L.V., Goldberg S. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl.) 2009, 204:607-616.
43. Hamdani N., Tabeze J.P., Ramoz N., Ades J., Hamon M., Sarfati Y., Boni C., Gorwood P. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur. Neuropsychopharmacol. 2008, 18:34-40.
44. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31:608-612.
45. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
46. Hides L., Lubman D.I., Buckby J., Yuen H.P., Cosgrave E., Baker K., et al. The association between early cannabis use and psychotic-like experiences in a community adolescent sample. Schizophr. Res. 2009, 112:130-135.
47. Hill M.N., Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav. Pharmacol. 2005, 16:333-352.
48. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 2005, 15:593-599.
49. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol. Disord. Drug Targets 2009, 8:451-458.
50. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., Gorzalka B.B. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30:508-515.
51. Hill M.N., Kambo J.S., Sun J.C., Gorzalka B.B., Galea L.A. Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur. J. Neurosci. 2006, 24:1845-1849.
52. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., Gorzalka B.B. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J. Neurochem. 2008, 106:2322-2336.
53. Hill M.N., Miller G.E., Carrier E.J., Gorzalka B.B., Hillard C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34:1257-1262.
54. Houchi H., Babovic D., Pierrefiche O., Ledent C., Daoust M., Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 2005, 30:339-349.
55. Hungund B.L., Vinod K.Y., Kassir S.A., Basavarajappa B.S., Yalamanchili R., Cooper T.B., Mann J.J., Arango V. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry 2004, 9:184-190.
56. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115:3104-3116.
57. Juhasz G., Chase D., Pegg E., Downey D., Toth Z.G., Stones K., Platt H., Mekli K., Payton A., Elliott R., Anderson I.M., Deakin J.F. CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 2009, 34:2019-2027.
58. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., Weis S. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural Transm. 2007, 114:1055-1063.
59. Lafenetre P., Chaouloff F., Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol. Res. 2007, 56:367-381.
60. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
61. Leweke F., Koethe D., Gerth C.W., et al. Double blind, controlled clinical trial of cannabidiol monotherapy versus amisulpiride in the treatment of acutely psychotic schizophrenia patients. Schizophr. Bull. 2007, 33:310.
62. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkotter J., Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 2007, 94:29-36.
63. Long L.E., Malone D.T., Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006, 31:795-803.
64. Lupica C.R., Riegel A.C., Hoffman A.F. Marijuana and cannabinoid regulation of brain reward circuits. Br. J. Pharmacol. 2004, 143:227-234.
65. Lutz B. The endocannabinoid system and extinction learning. Mol. Neurobiol. 2007, 36:92-101.
66. Luzi S., Morrison P.D., Powell J., di Forti M., Murray R.M. What is the mechanism whereby cannabis use increases risk of psychosis?. Neurotox. Res. 2008, 14:105-112.
67. Maccarrone M., Valverde O., Barbaccia M.L., Castane A., Maldonado R., Ledent C., Parmentier M., Finazzi-Agro A. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 2002, 15:1178-1186.
68. Madsen M.V., Peacock L., Werge T., Andersen M.B. Effects of the cannabinoid CB1 receptor agonist CP55, 940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. J. Psychopharmacol. 2006, 20:622-628.
69. Malone D.T., Taylor D.A. The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav. Brain Res. 2006, 166:101-109.
70. Malone D.T., Long L.E., Taylor D.A. The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol. Biochem. Behav. 2004, 77:839-845.
71. Malone D.T., Kearn C.S., Chongue L., Mackie K., Taylor D.A. Effect of social isolation on CB1 and D2 receptor and fatty acid amide hydrolase expression in rats. Neuroscience 2008, 152:265-272.
72. Mansbach R.S., Rovetti C.C., Winston E.N., Lowe J.A. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl.) 1996, 124:315-322.
73. Marcellino D., Carriba P., Filip M., Borgkvist A., Frankowska M., Bellido I., Tanganelli S., Muller C.E., Fisone G., Lluis C., Agnati L.F., Franco R., Fuxe K. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 2008, 54:815-823.
74. Marchalant Y., Brothers H.M., Norman G.J., Karelina K., DeVries A.C., Wenk G.L. Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol. Dis. 2009, 34:300-307.
75. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
76. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl.) 2002, 159:379-387.
77. Martin R.S., Secchi R.L., Sung E., Lemaire M., Bonhaus D.W., Hedley L.R., Lowe D.A. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl.) 2003, 165:128-135.
78. Martinez-Gras I., Hoenicka J., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero M.A., Perez-Hernandez E., Ampuero I., Ramos-Atance J.A., Palomo T., Rubio G. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:437-441.
79. McLaughlin R.J., Hill M.N., Morrish A.C., Gorzalka B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav. Pharmacol. 2007, 18:431-438.
80. Meltzer H.Y., Arvanitis L., Bauer D., Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2004, 161:975-984.
81. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., Di Marzo V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
82. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
83. Moreira F.A., Guimarães F.S. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur. J. Pharmacol. 2005, 512:199-205.
84. Moreira F.A., Aguiar D.C., Campos A.C., Lisboa S.F., Terzian A.L., Resstel L.B., Guimaraes F.S. Antiaversive effects of cannabinoids: is the periaqueductal gray involved?. Neural Plast. 2009, 2009:625469.
85. Morrish A.C., Hill M.N., Riebe C.J., Gorzalka B.B. Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission. Physiol. Behav. 2009, 98:118-124.
86. Nagai H., Egashira N., Sano K., Ogata A., Mizuki A., Mishima K., Iwasaki K., Shoyama Y., Nishimura R., Fujiwara M. Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol. Biochem. Behav. 2006, 84:330-336.
87. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 2006, 172:556-560.
88. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., Despres J.P., Kastelein J.J., Steinhubl S.R., Kapadia S., Yasin M., Ruzyllo W., Gaudin C., Job B., Hu B., Bhatt D.L., Lincoff A.M., Tuzcu E.M. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547-1560.
89. Oropeza V.C., Page M.E., Van Bockstaele E.J. Systemic administration of WIN 55, 212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 2005, 1046:45-54.
90. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
91. Perera T.D., Park S., Nemirovskaya Y. Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist 2008, 14:326-338.
92. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4:873-884.
93. Poncelet M., Barnouin M.C., Breliere J.C., Le Fur G., Soubrie P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl.) 1999, 144:144-150.
94. Przegalinski E., Gothert M., Frankowska M., Filip M. WIN 55, 212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. Eur. J. Pharmacol. 2005, 517:68-73.
95. Reich C.G., Taylor M.E., McCarthy M.M. Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav. Brain Res. 2009, 203:264-269.
96. Rodriguez-Gaztelumendi A., Rojo M.L., Pazos A., Diaz A. Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J. Neurochem. 2009, 108:1423-1433.
97. Roohbakhsh A., Moghaddam A.H., Massoudi R., Zarrindast M.R. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin. Exp. Pharmacol. Physiol. 2007, 34:223-229.
98. Rossi S., De Chiara V., Musella A., Kusayanagi H., Mataluni G., Bernardi G., Usiello A., Centonze D. Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J. Neurosci. 2008, 28:7284-7292.
99. Rubino T., Vigano D., Zagato E., Sala M., Parolaro D. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 2000, 35:8-14.
100. Rubino T., Viganò D., Premoli F., Castiglioni C., Bianchessi S., Zippel R., Parolaro D. Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol. Neurobiol. 2006, 33:199-213.
101. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., Parolaro D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008, 54:151-160.
102. Rubino T., Realini N., Castiglioni C., Guidali C., Vigano D., Marras E., Petrosino S., Perletti G., Maccarrone M., Di Marzo V., Parolaro D. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb. Cortex 2008, 18:1292-1301.
103. Rubino T., Vigano D., Realini N., Guidali C., Braida D., Capurro V., Castiglioni C., Cherubino F., Romualdi P., Candeletti S., Sala M., Parolaro D. Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 2008, 33:2760-2771.
104. Rubino T., Realini N., Braida D., Alberio T., Capurro V., Vigano D., Guidali C., Sala M., Fasano M., Parolaro D. The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox. Res. 2009, 15:291-302.
105. Scherma M., Medalie J., Fratta W., Vadivel S.K., Makriyannis A., Piomelli D., Mikics E., Haller J., Yasar S., Tanda G., Goldberg S.R. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008, 54:129-140.
106. Schneider M., Koch M. The cannabinoid agonist WIN 55, 212-2 reduces sensorimotor gating and recognition memory in rats. Behav. Pharmacol. 2002, 13:29-37.
107. Seifert J., Ossege S., Emrich H.M., Schneider U., Stuhrmann M. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci. Lett. 2007, 426:29-33.
108. Seillier A., Advani T., Cassano T., Hensler J.G., Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int. J. Neuropsychopharmacol. 2009, 1-14.
109. Sesack S.R., Carr D.B. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol. Behav. 2002, 77:513-517.
110. Sesack S.R., Pickel V.M. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res. 1990, 527:266-279.
111. Sewell R.A., Ranganathan M., D'Souza D.C. Cannabinoids and psychosis. Int. Rev. Psychiatry 2009, 21:152-162.
112. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., Rocha B.A. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 2003, 14:573-582.
113. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., Christiansen K., McRee B., Vendetti J. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002, 287:1123-1131.
114. Spano M.S., Fadda P., Frau R., Fattore L., Fratta W. Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur. Neuropsychopharmacol. 2010, 20:25-36.
115. Stefanis N.C., Delespaul P., Henquet C., Bakoula C., Stefanis C.N., Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004, 99:1333-1341.
116. Steiner M.A., Marsicano G., Nestler E.J., Holsboer F., Lutz B., Wotjak C.T. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008, 33:54-67.
117. Steiner M.A., Wanisch K., Monory K., Marsicano G., Borroni E., Bachli H., Holsboer F., Lutz B., Wotjak C.T. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J. 2008, 8:196-208.
118. Takahashi E., Katayama M., Niimi K., Itakura C. Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur. J. Pharmacol. 2008, 589:149-156.
119. Terzian A.L., Aguiar D.C., Guimaraes F.S., Moreira F.A. Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur. Neuropsychopharmacol. 2009, 19:188-195.
120. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., Nomikos G.G. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 2003, 138:544-553.
121. Uriguen L., Perez-Rial S., Ledent C., Palomo T., Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 2004, 46:966-973.
122. Vigano D., Guidali C., Petrosino S., Realini N., Rubino T., Di Marzo V., Parolaro D. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int. J. Neuropsychopharmacol. 2009, 12:599-614.
123. Wegener N., Kuhnert S., Thuns A., Roese R., Koch M. Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology (Berl.) 2008, 198:375-385.
124. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325:1199.
125. Zavitsanou K., Garrick T., Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:355-360.
126. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl.) 1991, 104:260-264.
127. Zuardi A.W., Morais S.L., Guimaraes F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56:485-486.
128. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., Crippa J.A. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 2006, 20:683-686.